The clinical practice for rheumatoid arthritis has dramatically changed during the recent couple of decades. The immuno-pathological mechanisms of autoimmune chronic arthritis have elucidated. Immune complexes consisting of citrullinated proteins and anti-citrullinated protein antibodies play a major role in the synovial inflammatory process, and inflammatory cytokines such as TNF-
α, IL-1, IL-6 derived from granulocytes, monocytes and macrophages play a major role in the destructive process of cartilage and bone tissue. Development of anti-cytokine molecular target drugs, i.e. biological DMARDs, has changed treatment strategies for rheumatoid arthritis. In accordance with this therapeutic innovation, diagnostic classification criteria were also revised in 2010 for the first time since 1986. Consequently, the treat to target (T2T) concept was introduced. These revolutionary changes have been called a paradigm shift in rheumatoid arthritis treatment. Medical rehabilitation has to change in concert with this revolution in medical practice concerning rheumatoid arthritis. Orthoses and assistive technologies help rheumatoid arthritis patients to prevent impairment and to restore body function and to maintain activities and participation. Detachable bandages and shoe inserts are useful for impairment prevention. For restoration of disability, foot orthoses, and ankle and knee orthoses are effective. Carefully selected and properly adjusted canes and walkers restore ambulation. Many kinds of assistive technical devices are utilized for regaining activities in patients with rheumatoid arthritis.
View full abstract